We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Recent events have yielded mixed results for life science companies trying to understand or track key technology regulations and standards, including the progress of electronic health initiatives coming out of the FDA. For example, the future of CFR 21 Part 11 — the agency’s regulations covering electronic records and electronic signatures — was left up in the air when the agency decided to not reschedule a June 11 meeting on the regulation, which had been cancelled as part of a national day of mourning for former President Ronald Reagan. The agency did hold a public meeting on the structured product labeling (SPL) standard in June and unveiled a new implementation timetable that gives industry more time to transition to the new specification for submitting drug labeling information electronically. The FDA also provided an update of key International Conference on Harmonisation initiatives, including the electronic common technical document, and HHS named a new IT czar and touted progress on ehealth records.